Adlai Nortye
Pharmaceuticals, 杭州, New Jersey, 08902, United States, 51-200 Employees
Phone Number: 86***********
Who is ADLAI NORTYE
Adlai Nortye is a global clinical-stage biotechnology company focused on innovative oncology drugs, with its R&D and global clinical operation centers in the US and China. The Company has...
Read More
-
Headquarters: 杭州, New Jersey, 08902, United States
-
Date Founded: 2016
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
Does something look wrong? Fix it. | View contact records from ADLAI NORTYE
Adlai Nortye Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Adlai Nortye
Answer: Adlai Nortye's headquarters are located at 杭州, New Jersey, 08902, United States
Answer: Adlai Nortye's phone number is 86***********
Answer: Adlai Nortye's official website is https://adlainortye.com
Answer: Adlai Nortye's revenue is $1 Million to $5 Million
Answer: Adlai Nortye has 51-200 employees
Answer: Adlai Nortye is in Pharmaceuticals
Answer: Adlai Nortye contact info: Phone number: 86*********** Website: https://adlainortye.com
Answer: Adlai Nortye is a global clinical-stage biotechnology company focused on innovative oncology drugs, with its R&D and global clinical operation centers in the US and China. The Company has built a global pipeline through collaborations and internal discovery with six drug candidates in pipeline. Currently, three of them are in clinical stage include (i) Buparlisib (AN2025), a pan-PI3K inhibitor in a global Phase III clinical trial, (ii) Palupiprant (AN0025), an oral EP4 antagonist is undergoing Phase 1b trial in combination with pembrolizumab in patients with multiple solid tumors; and (iii) AN4005, an oral small molecule PD-L1 drug which is currently in Phase I trial. In addition, a Phase I clinical trial has been initiated for a combination therapy consisting of AN2025, AN0025, and atezolizumab targeting a variety of PIK3CA mutant solid tumors. We also continue to advance three in-house preclinical programs include: AN8025, a multifunctional antibody as T cell and antigen-presenting cell (APC) modulator fusion protein; AN1025, an oral small molecule degrader of -catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month